Rilpivirine hydrochloride sustained release formulation (Brii Biosciences)

盐酸利匹韦林缓释制剂（腾盛博药）

Report date: 2023/04/03 10:20:19

Base Information

Drug NameRilpivirine hydrochloride sustained release formulation (Brii Biosciences)

Drug Alias NameBRII-778

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionHIV replication inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors

TargetsHuman immunodeficiency virus type 1 reverse transcriptase

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

ATC CodeN/A